IDXX — IDEXX Laboratories, Inc.

The immediate market tone is cautious: the stock is below all major moving averages and RSI is 43.2, not oversold, as investors apply a lower multiple even to high-quality healthcare names. Offsetting that, Q2 2026 beat with 10% revenue growth, roughly 35% operating margin, and guidance was raised; Wall Street consensus remains Buy with a $665 average target.

Revenue grew from $915M in Q3 2023 to $1.217B in Q2 2026, with FY2025 up ~10.4% and H1 2026 up ~11.8% YoY. Q2 2026 revenue rose ~9.7% YoY after Q1 2026 rose ~14.3%; that is mostly a tougher comparison, not deterioration. Operating margin expanded from ~30% in early 2024 to 35.0% in Q2 2026 versus 33.6% a year ago. Net income and EPS grew ~15% YoY in Q2 2026, and trailing twelve-month free cash flow jumped to roughly $1.25B from ~$727M a year earlier. This is margin expansion and cash-flow inflection, not a one-quarter blip.

At $545.08, TTM P/E is 38.3 and forward P/E is about 36.9 on FY2026 consensus EPS of $14.77. That is far below IDXX's 5-year average P/E of 54.0 and P/S of 12.3 versus 9.4 now. The PEG of 2.16 is not cheap in absolute terms, but for a company with a 25% net margin, 40% ROIC, and 10%+ revenue growth, the multiple is reasonable and historically inexpensive.

This is a de-rating, not an earnings collapse. FY2026 EPS guidance was raised to $14.69-$14.94 and Q2 EPS rose ~15% YoY, yet the stock has fallen from roughly $770 to $545. The market is paying about 37x forward earnings instead of the 45-55x it paid historically. If IDXX delivers 10-13% EPS growth, the current price already embeds a meaningful haircut; if rates stay high or growth dips below 10%, the lower multiple may be the new base.

As of 2026-08-27, RSI was 43.2 (neutral, not oversold), and price was -3.7% below its 20-day, -2.5% below its 50-day, and -10.9% below its 200-day moving average. The stock is hugging the lower end of its 52-week range after a downtrend, with no confirmed reversal. A break back above the 50-day would be the first timing signal, but the setup is more 'possible value zone' than 'clear entry.'

• Interest rate uncertainty continues to pressure high-multiple, long-duration growth stocks; IDXX's 38x P/E is more rate-sensitive than it was at 25x.
• Defensive healthcare rotation offers some support, but investors are being selective about which healthcare compounders deserve premium multiples.
• Structural pet-health tailwinds from the aging pandemic-era pet cohort are driving diagnostic utilization independent of the macro cycle.
• Foreign exchange is a modest headwind, with management absorbing roughly $15M of top-line FX pressure in 2026 guidance.
• Veterinary clinic staffing and visit volumes remain a swing factor; soft clinic traffic is the main operational check on recurring revenue growth.

• Q3 2026 earnings release in late October/early November 2026 will provide the next check on inVue Dx adoption and clinic visit resilience.
• Continued installed-base growth of inVue Dx (over 9,000 instruments and 1,600+ placements in Q2) and expansion of the Cancer Dx/FNA menu could drive upside.
• New Catalyst NT-proBNP cardiac test, launched August 2026, adds a new point-of-care revenue stream.
• Any Fed rate-cut signal or broad multiple re-rating could compress the large gap between IDXX's current 37x forward P/E and its 54x five-year average.
• Further fiscal 2026 guidance raises are possible if organic growth and margins keep trending above expectations.

• Valuation risk: even at 37x forward earnings, a sustained high-rate environment or growth downgrade could push the multiple lower.
• Companion animal diagnostics growth could decelerate if veterinary clinic visits weaken or if price/cost pressures drive clinics to defer testing.
• Competition in point-of-care diagnostics from Antech, Zoetis, Heska, and others could pressure share and pricing.
• Foreign exchange and international exposure create ongoing top-line and margin noise.
• The recent uptrend in FCF could normalize; quarterly cash flow has historically been lumpy, and the Q2 2025 base was unusually depressed.

IDXX is a high-quality compounder at a reasonable price after a roughly 29% drawdown from its high. The combination of mid-teens EPS growth, record operating margins, massive free cash flow, and a forward P/E near 37x versus a 54x five-year average makes this an attractive long-term risk/reward. The main missing ingredient is technical confirmation.

Applied a justified forward P/E of 42x to the FY2026E EPS midpoint of $14.82, about 22% below IDXX's 5-year average P/E of 54.0 but above the current 37x forward multiple, reflecting its 35% operating margin, 40% ROIC, and durable double-digit growth; this yields roughly $622.23.